Tizanidine Hydrochloride Capsule
Product Images NDC 70710-1112

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 70710-1112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals (usa) Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

16b0f047 2b7d 414c B0b8 0be4f495e3e3 01

Chemical structure diagram of tizanidine hydrochloride showing its molecular bonds and key elements, including chlorine (Cl), nitrogen (N), sulfur (S), and hydrogen chloride (HCl).*

FDA Label Image

16b0f047 2b7d 414c B0b8 0be4f495e3e3 02

A line graph showing plasma tizanidine concentration (ng/mL) over 24 hours post-dosing. It compares four groups each receiving 2 x 4 mg tizanidine doses in different forms and with/without food: tablets with food, tablets without food, capsules with food, and capsules without food. The graph illustrates concentration changes over time for these groups.*

FDA Label Image

16b0f047 2b7d 414c B0b8 0be4f495e3e3 03

A line graph depicting improvement in Ashworth Score over time (hours post-dose) comparing 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph shows higher improvement scores for 16 mg and 8 mg tizanidine compared to placebo, with values peaking around 2 hours post-dose then declining by 6 hours. Error bars represent variability at each time point.*

FDA Label Image

16b0f047 2b7d 414c B0b8 0be4f495e3e3 04

A line graph comparing the improvement in Ashworth Score between tizanidine (mean dose 28.8 mg) and placebo at three time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). The vertical axis shows improvement scores, with tizanidine showing consistent improvement and placebo showing little to no change.*

FDA Label Image

16b0f047 2b7d 414c B0b8 0be4f495e3e3 05

Tizanidine Hydrochloride Capsules 2 mg oral capsules packaging label. The label shows the 2 mg strength and quantity of 150 capsules. It includes a warning that these capsules are not interchangeable with tizanidine tablets or Zanaflex tablets. The manufacturer is Cadila Healthcare Ltd., India, and the product is distributed by Zydus Pharmaceuticals USA Inc. The label also provides storage instructions and notes traditional dosage information is on the package insert.*

FDA Label Image

16b0f047 2b7d 414c B0b8 0be4f495e3e3 06

Label for Tizanidine Hydrochloride Capsules 4 mg by Zydus Pharmaceuticals USA Inc. The label shows a blue and white capsule imprinted with "112", with a warning that these capsules are not interchangeable with tizanidine tablets or Zanaflex tablets. It states a quantity of 150 capsules and Rx only. Manufacturer and distributor information is also included.*

FDA Label Image

16b0f047 2b7d 414c B0b8 0be4f495e3e3 07

Tizanidine hydrochloride 6 mg capsules packaging label showing a single blue capsule image. The label includes a warning that these capsules are not interchangeable with tizanidine tablets or Zanaflex tablets. The package contains 150 capsules, is Rx only, and is distributed by Zydus Pharmaceuticals USA Inc. It also notes manufacturing by Cadila Healthcare Ltd., India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.